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Pulmonary hypertension (PH) contributes to the mortality of patients with lung and heart diseases. However, the underlying
mechanism has not been completely elucidated. Accumulating evidence suggests that inﬂammatory response may be involved
in the pathogenesis of PH. Macrophage migration inhibitory factor (MIF) is a critical upstream inﬂammatory mediator which
promotes a broad range of pathophysiological processes. The aim of the study was to investigate the role of MIF in the pulmonary
vascular remodeling of hypoxia-induced PH. We found that MIF mRNA and protein expression was increased in the lung
tissues from hypoxic pulmonary hypertensive rats. Intensive immunoreactivity for MIF was observed in smooth muscle cells
of large pulmonary arteries (PAs), endothelial cells of small PAs, and inﬂammatory cells of hypoxic lungs. MIF participated in
the hypoxia-induced PASMCs proliferation, and it could directly stimulate proliferation of these cells. MIF-induced enhanced
growth of PASMCs was attenuated by MEK and JNK inhibitor. Besides, MIF antagonist ISO-1 suppressed the ERK1/2 and JNK
phosphorylation induced by MIF. In conclusion, the current ﬁnding suggested that MIF may act on the proliferation of PASMCs
through the activation of the ERK1/2 and JNK pathways, which contributes to hypoxic pulmonary hypertension.
1.Introduction
Chronic pulmonary hypertension (PH) is a disease char-
acterized by a sustained pulmonary arterial pressure with
increases in pulmonary vascular resistance [1]. The patho-
genesis of PH has been ascribed to two mechanisms, the
initial event of vasoconstriction followed by remodeling of
small- and medium-sized pulmonary arteries which is a
hallmark of severe and advanced pulmonary hypertension.
The main pathological change related to vascular remod-
eling is an abnormal pulmonary artery smooth muscle
cells (PASMCs) hypertrophy and proliferation resulting in
obstruction of small pulmonary arteries [2, 3]. Recently,
more attention has been given to the facts that pulmonary
inﬂammation could contribute to hypoxic vasoconstriction
and remodeling. It has been reported that inﬂammatory cell
inﬁltrates in the areas of plexiform lesions in human severe
chronic pulmonary arterial hypertension [4]. Circulating
inﬂammatory and/or progenitor cells contribute to hypoxia-
induced pulmonary vascular remodeling [5, 6]. In addition,
accumulating evidence conﬁrms that chronic hypoxia results
in the increased expression of lung inﬂammatory cytokines
and chemokines, including interleukin-1 (IL-1), interleukin-
6 (IL-6), tumor-necrosis-factor-α (TNF-α), and Fractalkine,
which may potentiate the development of PH [7–10]. For
instance, IL-6 promotes the development and progression
of pulmonary vascular remodeling and PH through pro-
proliferative antiapoptotic mechanisms [8]. Fractalkine may
contribute to PASMCs proliferation in PH [10]. Therefore,
there is a growing interest in inﬂammatory mediators in the
pulmonary hypertensive process.2 Mediators of Inﬂammation
Macrophage migration inhibitory factor (MIF) was orig-
inally identiﬁed as a T-cell-derived cytokine that inhibits
the random migration of macrophages [11]. Currently, MIF
is proved to be an important proinﬂammatory cytokine,
secreted by most of the cells including T cells, macropha-
ges/monocytes, endothelial cells, and smooth muscle cells
and induce the production of a large number of inﬂam-
matory mediators, such as TNF-α,I L - 1 β, IL-6, and IL-8
[12, 13]. Thus, many studies revealed MIF to be involved
in the pathogenesis of inﬂammatory diseases, such as ath-
erosclerosis, rheumatoid arthritis, sepsis, asthma, and acute
respiratory distress syndrome [14–18]. Besides, MIF may act
beyond inﬂammatory cytokine, as suggested by its prolifera-
tive eﬀect on vascular smooth muscle cells demonstrated in
atherosclerosis [19]. The evidence provides an idea that MIF
might play a role in the vascular disease. However, there is
no report that MIF participates in the pulmonary vascular
remodeling during exposure to chronic hypoxia.
In the present study, we hypothesized that MIF may have
a role in pulmonary vascular remodeling. For that purpose,
the expression of MIF was examined in the lungs of hypoxic
pulmonary hypertensive (HPH) rats. Then we investigated
the eﬀect of MIF on hypoxia-induced PASMCs proliferation
and the underlying mechanism.
2.MaterialandMethods
2.1. Animals, Drugs, and Chemicals. Male Sprague-Dawley
rats (body weight 200–250g) were used. All of the exper-
imental procedures were approved by the Animal Use and
Care Committee for Research and Education of the Fourth
Military Medical University. Recombinant mouse MIF was
purchased from R&D Systems (Minneapolis, MN, USA).
ISO-1wasobtainedfromCalbiochem(SanDiego,CA,USA).
MTT,PD 98059, SB203580, andSP600125 werefromSigma
(St. Louis, MO, USA). MIF monoclonal antibody against
rats MIF was gifted from Dr. Chuan-Min Hu, the Third
Military Medical University, Chong Qing, China. Antibodies
to ERK1/2 and phospho-ERK1/2, JNK and phospho-JNK
were from Cell Signaling (Beverly, MA, USA). The inhibitors
were dissolved in dimethyl sulfoxide (DMSO). The ﬁnal
amount of DMSO in the bath solution was less than 0.1%.
2.2. Treatment of Rat. According to the previous reports, rats
were housed intermittently in a chamber containing 10%
oxygen, for exposure to continuous hypobaric hypoxia [20].
The intermittent regime consisted of 10 hours in the hypoxic
chamber followed by 14 hours in room air (21% oxygen).
Rats were exposed to these conditions for a total of 28 days.
The normoxic control rats were housed continuously in
room air. At the end of hypoxia exposure, measurement of
the right ventricle systolic pressure (RVSP) and the ratios of
right ventricle/[left ventricle + septum] (RV/[LV+S]) weight
were determined. Increases in RVSP and RV/[LV+S] were
taken as indicators of pulmonary hypertension.
2.3. Cell Culture and Treatment. Rats PASMCs were cultured
from explants as previously described [20]. Brieﬂy, as soon
as median sternotomy was performed, lungs were removed
with hearts in fresh PBS. Under a dissecting microscope, the
2nd-3rd-division (external diameter <300μm) pulmonary
arteries were isolated carefully. After the adventitial layers
together with the surrounding tissue and endothelium were
removed, the pulmonary arteries were dissected into small
pieces and cultured in DMEM supplemented with 100U/mL
penicillin, 0.1mg/mL streptomycin, 2mM L-glutamine, and
10%FBSandgrowninhumidiﬁedincubatorsat37◦Cin95%
O2and 5% CO2. Cells were used for experiments between
passages 3 and 6. In the hypoxic groups, PASMCs were
transferred into a hypoxic chamber containing 2% O2,5 %
CO2, and 93% N2 for 24 hours. Before exposure to hypoxia
or treatment with diﬀerent agents, cells were undergone
serum starvation for 36 hours. Cells were exposed to hypoxia
or treated with diﬀerent agents in 1% FBS DMEM.
2.4. Immunohistochemistry. R i g h tl u n gs a g i t t a ls e c t i o n sw e r e
placed in 4% paraformaldehyde and processed for paraﬃn
embedding. Sections (5μm) were cut and mounted on the
glass slides. Endogenous peroxidase activity was quenched
with 3% peroxide for 10 minutes. The sections were incu-
bated overnight at 4◦C with anti-MIF antibody. Slides were
washed and incubated with the corresponding secondary
antibodies conjugated with alkaline phosphatase.
2.5. RT-PCR. Lungs were homogenized, and total RNA was
extracted from the lung tissues by using the RNeasy Total
RNA Isolation Kit (Qiagen, Valencia, CA). The primers
for the rat MIF gene were sense, 5 -TCTCCGCCACCA-
TGCCTATG-3 , and antisense, 5 -GGGTCGCTCGTGCCA-
CTAAA-3 , and for the housekeeping gene β-actin were
sense, 5 -ATCATGTTTGAGACCTTCAACA-3 ,a n da n t i -
sense, 5 -CATCTCTTGCTCGAAGTCCA-3 .P C Rr e a c t i o n
was carried out under the following conditions: 30 cycles of
denaturation at 94◦C for 30s, annealing at 56◦C for 30s, and
extensionat72◦Cfor30s.Aﬁnalextensionwasperformedat
72◦C for 1min. PCR products were separated by 1% agarose
gel electrophoresis.
2.6. Western Blot Analysis. Total lysates were obtained
from harvested lung tissues and cultured PASMCs. Lung
homogenates were prepared in RIPA lysis buﬀer, containing
50mM Tris (pH 7.4), 150mM NaCl, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 2mM NaF, 5mM EDTA
(pH 8.0), and 1mM sodium orthovanadate (Beyotime Inc,
Jiangsu, China). The protease inhibitor of phenylmethylsul-
fonyl ﬂuoride (PMSF, 1mM) was added to the RIPA buﬀer
in advance. Equivalent amounts of protein (30μg) from
each sample were separated on 12% SDS-polyacrylamide
gels and then transferred onto 0.22μm nitrocellulose ﬁlter
membranes (Millipore, Bedford, USA). The membrane was
blocked and incubated with primary antibodies for MIF,
or phosphospeciﬁc ERK1/2, ERK1/2, phospho-JNK, and
JNK. The levels of proteins and phosphoproteins were
detected with enhanced chemiluminescent substrate (Pierce,
Rockford, IL, USA).
2.7. Cell Proliferation Assay. Cells were seeded into 96-well
plates and then incubated in medium containing 0.1%Mediators of Inﬂammation 3
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Figure 1: MIF expression in rat lung homogenates. (A) MIF expression was measured by RT-PCR before and after hypoxia exposure. There
was a marked upregulation of MIF in the lungs from hypoxic rat (a). Bar graph showed MIF mRNA levels obtained from quantitative
densitometry analysis (b). (B) Western blot analysis demonstrated that MIF protein was increased in rat lung homogenates after hypoxia
exposure (a). Bar graph showed MIF protein levels obtained from quantitative densitometry analysis (b). n = 5.
∗P < 0.05 versus control.
DMEM. MIF (50, 100, 200ng/mL) or PD 98059 (20μM),
SB 203580 (20μM) and SP 600125 (20μM) and ISO-1 (10,
50, 100μM) were added, respectively. After being cultured
for24hoursundernormoxic condition orhypoxia exposure,
solution MTT was added into each well with a 5mg/mL con-
centration. Cells were cultured for another 4 hours, and then
dimethyl sulfoxide (DMSO) was added in. After vibrating
for 10 minutes, the optical density values were detected at
490nm wavelength by using a spectrophotometer (Bio-Tek
Power Wave XS, USA). Additionally, cell proliferation was
evaluatedbydirectcellcounting.PASMCswereseededin12-
well plates and cultured. Cells were stimulated with MIF or
inhibitors asdescribed above, respectively,and after24 hours
they were harvested by mild trypsinization and counted with
a hemocytometer.
2.8. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n±
SD. Statistical analysis was processed by using one-way
ANOVA, followed by LSD test for post hoc multiple com-
parisons (SPSS for Windows version 16.0, Chicago, USA).
Diﬀerences were considered to be signiﬁcant when P<0.05.
3. Results
3.1. Haemodynamics and Right Ventricular Hypertrophy.
Rats exposed to hypoxia for 28 days developed pulmonary
hypertension (Table 1), as demonstrated by an increase in
RVSP (48±2.8mmHg in hypoxic rats versus 23±0.5mmHg
incontrolrats)(n = 8,P<0.05)andtheratiosofRV/(LV+S)
weight (0.41 ± 0.05 in hypoxic rats versus 0.26 ± 0.02 in
control rats) (n = 10, P<0.05).4 Mediators of Inﬂammation
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Figure 2: Immunohistochemical analysis of MIF in rat lungs. Immunostaining with an antibody to MIF of normoxic lungs ((a)–(c))
compared with lungs from hypoxic rats ((d)–(f)). The results showed no positive immunoreactivity for MIF in the pulmonary vasculature
in control rats (arrow in (a) and (b)), but MIF stained smooth muscle cells of large pulmonary arteries (arrow in (d)), endothelial cells of
small pulmonary arteries (arrow in (e)), and inﬂammatory cells around the alveoli (arrow in (f)) strongly in hypoxic lung sections. Arrows
in (c) reveal normal alveoli. Arrowheads in (b) and (e) depict intense staining of bronchial epithelial cells.
Table 1: Haemodynamic variables and right ventricle hypertrophy
index.
Group n RVSP (mmHg) RV/(LV+S)
Control 8 23 ±0.50 .26 ±0.02
Hypoxia 10 48 ±2.8∗ 0.41 ±0.05∗
Rats were housed intermittently in a hypobaric hypoxia chamber containing
10% oxygen and exposed to these conditions for 10h/d continuing 28 days.
Right ventricle systolic pressure (RVSP) and the ratios of right ventricle/[left
ventricle + septum] (RV/[LV+S]) weight were examined as indicators of
pulmonaryhypertension.Valuesaremeans ±SD. ∗P<0.05,comparedwith
the corresponding value in control rats.
3.2. MIF Expression in Rat Lungs. Lung homogenates
from hypoxic rats showed increases in both MIF mRNA
(Figure 1(A)) and protein (Figure 1(B)) compared with con-
trol rats. As the immunohistochemistry results show, there
was MIF staining in bronchial epithelial cells (Figure 2(b)),
but no positive immunoreactivity for MIF in the pulmonary
vasculature in control rats (Figures 2(a) and 2(b)), while
intense MIF staining of smooth muscle cells of large pul-
monary arteries (diameter >100μm) (Figure 2(d)), endothe-
lial cells of smaller PA (diameter <100μm), and bronchial
epithelial cells (Figure 2(e)), as well as the inﬂammatory cellsMediators of Inﬂammation 5
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Figure 3: Eﬀects of MIF inhibition on rat PASMCs proliferation
under hypoxia exposure. PASMCs proliferation was measured by
MTT (a) and direct cell counting (b). Hypoxia-induced PASMCs
proliferation was inhibited by diﬀerent concentrations of MIF
antagonist ISO-1 (10, 50, 100μM). n = 6.
∗P < 0.05 versus
normoxic control; #P < 0.05 versus vehicle-treated hypoxia group.
around the alveoli (Figure 2(f)), was observed in hypoxic
lungs.
3.3. MIF-Induced Proliferation of Rat PASMCs. It is known
that hypoxia exposure signiﬁcantly increases the PASMCs
proliferation, but we found that this proliferation was
obviously inhibited by three various concentrations of MIF
antagonist ISO-1 (Figure 3, P<0.05). ISO-1 had no
eﬀect on normoxic control PASMCs proliferation. Since
we have established that hypoxia enhanced MIF expression
and MIF contributed to the hypoxia-induced proliferation
of PASMCs, we further tested the direct eﬀect of MIF on
PASMCs proliferation. Both MTT assay and cell counting
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Figure 4: Eﬀects of MIF on proliferation of rat PASMCs. Cell
proliferationwasdemonstratedbyMTT(a)anddirectcellcounting
(b). MIF (100, 200ng/mL) could directly promote PASMCs prolif-
eration. n = 8.
∗P < 0.05 versus control.
showed that higher concentration (100, 200ng/mL) of MIF
could directly stimulate PASMCs proliferation (Figure 4).
3.4. MIF Stimulates PASMCs Proliferation through Acti-
vation of ERK1/2 and JNK. As shown in Figure 5(a),
100ng/mL MIF-induced PASMCs proliferation was signif-
icantly blocked by speciﬁc MEK inhibitor PD 98059 and
JNK inhibitor SP 600125 (P<0.05), but not by p38
MAPK inhibitor SB 203580. The similar results were found
as evaluated by cell counting (Figure 5(b)). These results
suggested that ERK1/2 and JNK were involved in MIF
proliferative pathway.
3.5. ERK1/2 and JNK Activation in MIF-Stimulated PASMCs.
We found that MIF could activate phosphorylation of6 Mediators of Inﬂammation
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Figure 5: MIF-induced rat PASMCs proliferation is dependent on
ERK1/2 and JNK activation. Cell proliferation was demonstrated
by MTT (a) and direct cell counting (b). PASMCs proliferation
stimulated by MIF (100ng/mL) was blocked by the MEK inhibitor
(PD 98059, 20μM) and JNK inhibitor (SP 600125, 20μM), whereas
the p38 MAPK inhibitor (SB 203580, 20μM) had no eﬀect. n = 8.
∗P < 0.05 versus vehicle-treated control; #P < 0.05 versus groups
treated with MIF alone.
ERK1/2 and JNK. 100ng/mL MIF-induced ERK1/2 activa-
tion was increased in a rapid time-dependent manner with
maximal at 30min and followed by a downregulation of
ERK1/2 phosphorylation after 60min (Figure 6(A)). MIF
could also activate phosphorylation of JNK with peaks
at 60min (Figure 6(B)). Treatment with ISO-1 (50μM),
MIF-induced both ERK1/2 and JNK activation was attenu-
ated markedly (Figure 7).
4. Discussion
Chronic hypoxic exposure induces changes in the structure
of pulmonary artery which is associated with increased
pulmonary vascular resistance, pulmonary hypertension,
andrightheartfailure.However,themechanismsstillremain
unclear. The present study provides evidence that MIF is
upregulated in the lungs of HPH rats and stimulates rats
PASMCs proliferation, indicating a possible role for this
cytokine in the pathogenesis of PH.
Investigations revealed that chronic hypoxia induced
upregulation of gene expression of a wide spectrum of
proinﬂammatorymediators,includingchemokinesandtheir
receptors, cytokines, growth and diﬀerentiation factors, and
adhesionandﬁbrosis-associatedmolecules[21].Itisincreas-
inglyappreciatedthatinﬂammatorymediatorscoulddirectly
contribute to the pulmonary vascular remodeling. They have
signiﬁcant eﬀects on the local vascular wall cells, including
increases in proliferation and matrix protein production
[22]. It is reported that IL-6 may aﬀect pulmonary vascular
remodeling via direct stimulation of vascular smooth muscle
cell (SMC) migration or by indirect eﬀects on vascular
SMC proliferation [23]. In addition, increased serum level
of IL-1β was observed in the serum of patients with
severeprimarypulmonaryhypertension[24].Theseﬁndings
suggest that inﬂammatory mediators are closely associated
with pulmonary hypertensive process.
As a critical proinﬂammatory cytokine, MIF is consti-
tutively expressed in a variety of immune and nonimmune
cells and also eﬀectively secreted from various phenotype
cells into the circulation [25]. Upon secretion, MIF exhibits
broad regulatory properties, including stimulation of the
growth of a number of cell lines, except for a key mediator
in a number of immune and inﬂammatory diseases. Yang
detected that MIF was a potent human-endothelial-cell-
growth-promoting agent [26]. Neutralizing MIF bioactivity
in atherosclerosis-susceptible mice reduces vascular SMC
proliferation and neointimal thickening [19]. Additionally,
Fu et al. found that MIF mediated the hypoxia response
of vascular SMC, including cell migration and proliferation
[27]. In human, it is reported that patients with PH showed
higher MIF levels than patients without these manifestations
in systemic sclerosis. It was suggested that MIF might
contribute to vascular complications [28]. However, no
studies have yet addressed the role of MIF in PASMCs pro-
liferation in the pulmonary circulation exposed to hypoxia.
Therefore,itwillbeofinteresttoexplorewhetherMIFaﬀects
PASMCs proliferation during exposure to chronic hypoxia
and contributes to the pulmonary vascular remodeling. In
the current study, we found that both MIF mRNA and
protein expression were increased in the lung tissues from
HPH rats. Furthermore, the increased MIF mostly located
in smooth muscle cells of large pulmonary arteries and
endothelial cells of smaller PA, as well as the inﬂammatory
cells and bronchial epithelial cells. These results indicated
that MIF overexpression under hypoxia exposure condition
might inﬂuence the cells in the vascular walls. Due to the
key role of PASMCs in HPH, we examined the eﬀect of MIF
on hypoxia-induced PASMCs proliferation. As the resultsMediators of Inﬂammation 7
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Figure 6: MIF induced ERK1/2 and JNK phosphorylation in rat PASMCs. PASMCs were treated with MIF (100ng/mL) for diﬀerent time
points. Signiﬁcant ERK1/2 (A) and JNK (B) phosphorylation was induced after 15min of MIF treatment. (A) Cell lysates were subjected to
immunoblotting analysis using antibodies against phospho-ERK1/2 (p ERK1/2) and total ERK1/2 (a). Bar graph showed ERK1/2 protein
levels obtained from quantitative densitometry analysis (b). (B) Cell lysates were subjected to immunoblotting analysis using antibodies
against phospho-JNK (p JNK) and total JNK (a). Bar graph showed JNK protein levels obtained from quantitative densitometry analysis (b).
n = 5.
∗P < 0.05 versus control.
show, the isolated PASMCs proliferated in response to
hypoxia,whichwasconsistentwithpreviousreports[29,30].
Yet hypoxia-induced PASMCs proliferation was signiﬁcantly
attenuated by MIF antagonist ISO-1. ISO-1 is a small
molecule inhibitor targeting MIF which inhibits the catalytic
site of MIF and leads to a marked reduction in the biological
function of MIF [31, 32]. Next, to observe the direct stimu-
latory eﬀect of MIF on PASMCs growth, recombinant MIF
was administrated to cells. We also found that MIF could
promote PASMCs proliferation. However, there is evidence
showing that proliferation of PASMCs was not aﬀected by
exogenous MIF [33]. The diﬀerent isolated PASMCs may
account for the diﬀerence in response to MIF. We also added
1% FBS to the culture medium which may contribute to the
stimulated eﬀect of MIF. Thus, our ﬁndings add MIF to the
list of proliferative agents which may contribute to PASMCs
proliferation in PH. Although MIF is a weak stimulator of
proliferation, it might work in combination with something
else such as other inﬂammatory mediators, or its receptor
expression is altered during hypoxia exposure, which needs
to be further studied.
Mitogen-activated protein kinases (MAPKs), including
extracellular signal-regulated kinase (ERK), c-Jun NH2-
terminal kinase (JNK), and p38 MAP kinase (p38), play
the critical role in cell proliferation, survival, or apoptosis
[34,35].StudieshaveimpliedthatMIF-mediatedsignalingis
associated with a sustained phosphorylation and activation
of the p44/p42 ERK1/2 subfamily of MAPK [36, 37]. On8 Mediators of Inﬂammation
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Figure 7: Eﬀects of MIF inhibition on phosphorylation of ERK1/2 and JNK in rat PASMCs. MIF-stimulated ERK1/2 and JNK
phosphorylation for 60min was inhibited by MIF antagonist ISO-1 (50μM). (A) Cell lysates were analyzed by immunoblotting using
antibodies speciﬁc for phospho-ERK1/2 (p ERK1/2) and total ERK1/2 (a). Bar graph showed ERK1/2 protein levels obtained from
quantitative densitometry analysis (b). (B) Cell lysates were analyzed by immunoblotting using antibodies speciﬁc for phospho-JNK (p
JNK) and total JNK (a). Bar graph showed JNK protein levels obtained from quantitative densitometry analysis (b). n = 6.
∗P < 0.05 versus
vehicle-treated control; #P < 0.05 versus groups treated with MIF alone.
the other hand, MIF could mediate phosphorylation of JNK
in septic shock [38] and utilizes the JNK pathway in T cells
and ﬁbroblasts [39]. Also, MIF treatment strongly activated
ERK1/2andp38MAPKinendometrioticcells[40].Chenget
al. showed that MIF mediated adhesion molecule expression
via the promotion of p38 MAPK activation in human
endothelial cells [41]. Although MIF has been reported to
activate MAPK signaling in several phenotype cells, there
is no available information on the role of MAPK pathway
in MIF-induced PASMCs response. Here, we demonstrated
thatMEKandJNKinhibitorsblockMIF-stimulatedPASMCs
growth, respectively. ISO-1 also inhibited MIF-activated
phosphorylation of ERK1/2 and JNK. Thus, our ﬁndings
support the idea that ERK1/2 and JNK signaling participate
in the MIF proliferative pathway. But our ﬁndings also
show that p38 MAPK did not appear to contribute to
MIF-promotedPASMCsproliferation.Thepreviousﬁndings
of Amin reported that MIF-induced migration of human
dermal microvascular endothelial cells was not blocked by
inhibitors of Src and p38 MAPK [42]. It indicated that
MIF mediated the various eﬀects through diﬀerent signal
transduction pathways in diﬀerent cell types.
In summary, the current study showed that MIF expres-
sion was increased in the lungs from HPH rats. This cytokine
may act as a growth factor for PASMCs partially through
ERK1/2 and JNK pathway without the involvement of p38
MAPK. We conclude that MIF contributes to the hypoxic
pulmonary hypertension, but further studies will be neededMediators of Inﬂammation 9
to extend these ﬁndings, with the aim of identifying new
therapeutic targets for treatment of pulmonary hyperten-
sion.
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